Delivery Order SPE2DB22D1103-SPE2DB25FH1D9
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $6,351.04 to AmerisourceBergen Drug Corp for the supply of Multaq 400 mg tablets (60-count units) on August 27, 2025, with an ultimate completion date of August 28, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a small-value transaction under...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Multaq 400 mg tablets in quantities of 60 units. This firm fixed-price delivery order, valued at $5,068.62, is set to be completed by August 11, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a non-competitive delivery order issued under AmerisourceBergen's existing contract vehicle with DLA, reflecting...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Multaq 400 mg tablets (60-count units) valued at $11,985.90. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is classified as a delivery order, with an ultimate completion date of August 13, 2025. The pharmaceutical product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Multaq 400 mg tablets (60-count units) valued at $7,902.75 under a firm fixed-price contract. This non-set-aside delivery order represents a routine pharmaceutical procurement supporting federal medical supply needs, with an ultimate completion date of August 15, 2025. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a $3,405.18 delivery order to AmerisourceBergen Drug Corp on August 12, 2025, for the supply of Multaq 400 mg tablets (60-count). The contract is a firm fixed price delivery order with an ultimate completion date of August 13, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This award represents a non-set-aside, competitively awarded transaction, reflecting the contractor's established capability to meet federal...
- The U.S. Department of Defense Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $20,853.40 for 60 tablets of Multaq 400 mg on July 21, 2025, with an ultimate completion date of July 22, 2025. This non-set-aside contract utilizes firm fixed price terms and represents a single delivery order under a larger indefinite delivery contract vehicle. The point of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen's corporate office operates as...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,549.80 on July 29, 2025, for the supply of Multaq 400 mg tablets (60-count units). This is a firm fixed-price, competitively awarded contract with no set-aside designation and a completion date of July 30, 2025. The contract will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's broader...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Multaq 400 mg tablets (60-count units) with a ceiling value of $3,241.33. This firm fixed-price delivery order, with an ultimate completion date of July 28, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The award was competitively awarded with no set-aside designation. AmerisourceBergen, a...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Multaq 400 mg tablets (60-count units) valued at $8,120.96. This firm fixed-price delivery order, which must be completed by August 20, 2025, represents a competitively awarded contract with no set-aside designation. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Multaq 400 mg tablets (60-count packages) valued at $2,515.53. This firm fixed-price delivery order is set to conclude on August 8, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a non-competitive delivery order issued under an existing contract vehicle, reflecting the company's...
- SPE2DB22D1103Indefinite Delivery Contract
- SPE2DB22D1103-SPE2DB25FH1D9Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $4,016.76 on August 27, 2025, for the supply of Multaq 400 mg tablets (60-count units). This non-set-aside, firm fixed-price delivery order is scheduled for completion by August 28, 2025, with performance at the contractor's facility in Conshohocken, Pennsylvania. The award represents a continuation of AmerisourceBergen's role as a critical pharmaceutical supplier to the federal government, particularly for military and veteran healthcare systems. This delivery order operates under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The parent contract serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a wide range of medications, vaccines, and medical supplies to support military healthcare programs worldwide. AmerisourceBergen's consistent receipt of competitively awarded, non-set-aside contracts across multiple therapeutic domains demonstrates its established capability to meet rigorous federal procurement standards for pharmaceutical products and medical commodities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.0k | 8/27/25 |